Female Testosterone MDTS

Our Lead Development Program

Advancing a new treatment option for women's health

Acrux is developing a novel Female Testosterone Metered Dose Transdermal Spray (MDTS) for postmenopausal women experiencing hypoactive sexual desire disorder (HSDD), a condition characterised by persistent low sexual desire associated with personal distress.

• There is currently no FDA-approved testosterone treatment specifically for women in the United States, highlighting a significant unmet medical need.
• Building on completed Phase I and Phase II clinical studies, Acrux is progressing towards Phase III clinical development following recent regulatory engagement with the US Food and Drug Administration (FDA).
• The Company's proprietary MDTS technology is designed to deliver controlled, female-appropriate doses of testosterone through a convenient, once-daily transdermal spray.

FDA Perspectives on Testosterone Treatment for Women

Hear perspectives from the FDA's public workshop on testosterone treatment for women, including the unmet medical need and considerations for future treatment development.